← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
University Of Western Australia
Crawley
$10,696,042
Total funding
22
Grants
Funding over time
peak $2.6M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,784,960 · 9
DOD$3,911,082 · 13
By mechanism
R01$6,482,962 · 7
—$3,911,082 · 13
R21$296,998 · 1
R13$5,000 · 1
Investigators at University Of Western Australia
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
IMPROVING MESOTHELIOMA THERAPY BY BOOSTING IMMUNE RESPONSES TO MUTATIONS BY VACCINATION AND BY IMMUNOGENIC CHEMOTHERAPY$999,875
· FY2020 · Defense Health Agency
TRANSFER RNA-DERIVED FRAGMENTS AS NOVEL DIAGNOSTIC AND FUNCTIONAL TARGETS FOR MALIGNANT MESOTHELIOMA$540,000
· FY2020 · Department of the Army
Emotion Regulation in Distress Disorders: Elucidating the Role of Cognitive Processes and Person-Situation Fit in the Laboratory and Daily Life$505,612
R01 · FY2019 · MH
Emotion Regulation in Distress Disorders: Elucidating the Role of Cognitive Processes and Person-Situation Fit in the Laboratory and Daily Life$449,333
R01 · FY2022 · MH
Emotion Regulation in Distress Disorders: Elucidating the Role of Cognitive Processes and Person-Situation Fit in the Laboratory and Daily Life$441,529
R01 · FY2020 · MH
Emotion Regulation in Distress Disorders: Elucidating the Role of Cognitive Processes and Person-Situation Fit in the Laboratory and Daily Life$428,695
R01 · FY2021 · MH
Emotion Regulation in Distress Disorders: Elucidating the Role of Cognitive Processes and Person-Situation Fit in the Laboratory and Daily Life$399,163
R01 · FY2023 · MH
TARGETED EPIGENETIC MODIFICATION TO IMPROVE MESOTHELIOMA RESPONSES TO IMMUNOTHERAPY$398,881
· FY2020 · Defense Health Agency
THE MEXTAG COLLABORATIVE CROSS: UNDERSTANDING GENETIC MODIFIERS IN MESOTHELIOMA$394,281
· FY2018 · Department of the Army
DEVELOPING NOVEL STRATEGIES TO UNCOUPLE IMMUNOTHERAPY-INDUCED AUTOIMMUNITY FROM ANTITUMOR IMMUNITY$376,596
· FY2022 · Defense Health Agency
CONNECTIVITY OF AUSTRALIAN NORTHWEST SHELF AND LEEUWIN CURRENT$301,820
· FY2011 · Department of the Navy
TARGETING IMMUNOLOGICAL "RESTRAINERS": UNDERSTANDING THE IMMUNOLOGY BEHIND COMBINATION CHEMOIMMUNOTHERAPY TO IMPROVE THE TREATMENT$269,850
· FY2012 · Department of the Army
MOLECULAR MECHANISMS OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY IN MESOTHELIOMA$258,047
· FY2020 · Department of the Army
Targeted epigenetic silencing of oncogenic Transcription Factors (PQ18)$247,767
R01 · FY2015 · CA
Asthma medication delivery with a new incentive spacer$243,000
R01 · FY2003 · HL
Asthma medication delivery with a new incentive spacer$243,000
R01 · FY2004 · HL
Antisense oligonucleotide suppression of non-deletion DMD causing mutations$235,110
R01 · FY2012 · NS
Antisense oligonucleotide suppression of non-deletion DMD causing mutations$232,837
R01 · FY2009 · NS
Antisense oligonucleotide suppression of non-deletion DMD causing mutations$228,316
R01 · FY2011 · NS
Antisense oligonucleotide suppression of non-deletion DMD causing mutations$223,984
R01 · FY2010 · NS